Central Pharmaceutical JSC No2

Central Pharmaceutical JSC No2 EBIT per Share

The EBIT per Share of Central Pharmaceutical JSC No2 (DP2.VN) as of Nov 22, 2026 is 309.11 VND. In the previous year, EBIT per Share was -45.33 VND — a change of -781.98% (higher).

EBIT per Share

309.11VND

YoY

-781.98%

Last updated:

EBIT per Share of Central Pharmaceutical JSC No2 is 2025 309.11 VND. EBIT per Share of Central Pharmaceutical JSC No2 was 2024 -45.33 VND. It decreases by -781.98% higher compared to the previous year.

The Central Pharmaceutical JSC No2 EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-49.95 VND
Jan 1, 2019
-247.95 VND
Jan 1, 2020
-640.05 VND
Jan 1, 2021
-329.25 VND
Jan 1, 2022
-486.86 VND
Jan 1, 2023
-368.34 VND
Jan 1, 2024
-45.33 VND
Jan 1, 2025
309.11 VND
The Central Pharmaceutical JSC No2 EBIT per Share history
YEAREBIT per ShareYoY
309.11VND-781.98%
-45.33VND-87.69%
-368.34VND-24.34%
-486.86VND+47.87%
-329.25VND-48.56%
-640.05VND+158.14%
-247.95VND+396.40%
-49.95VND-122.90%
218.12VND-117.43%
-1,251.20VND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Central Pharmaceutical JSC No2 Stock analysis

What does Central Pharmaceutical JSC No2 do? Central Pharmaceutical JSC No2 generates revenue through manufacturing and distributing pharmaceutical products such as broad-spectrum antibiotics, tablets, liquid medicines, ointments, capsules, and topical balms. The company also engages in importing and trading medicinal materials and preparations. Its primary customers are healthcare providers and pharmacies across Vietnam, focusing on domestic markets for diversified pharmaceutical solutions. The firm operates within the pharmaceutical sector, leveraging its manufacturing capabilities to supply essential medicines. It targets healthcare institutions and retail pharmacy chains that require consistent access to a wide range of pharmaceutical products. Central Pharmaceutical JSC No2’s business model emphasizes local production and distribution to meet regional demand without relying on international markets or external partnerships. Revenue streams are derived from both product sales and import-trading activities. The company’s product portfolio includes antibiotics, dosage forms like tablets and capsules, and topical treatments such as ointments and balms. These offerings cater to the domestic Vietnamese healthcare sector, where demand for affordable and accessible medicines remains strong. Central Pharmaceutical JSC No2 is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Central Pharmaceutical JSC No2 stock

EBIT per Share of Central Pharmaceutical JSC No2 is 309.11 VND in 2025.

EBIT per Share of Central Pharmaceutical JSC No2 changed from -45.33 VND to 309.11 VND, representing a -781.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Central Pharmaceutical JSC No2 since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Central Pharmaceutical JSC No2

All Key Metrics — Central Pharmaceutical JSC No2